Eribulin is named as a drug or biological intervention in 21 clinical trials in our China, USA, UK and India trial registers, 10 of which are recruiting. Lead sponsors include BioNTech SE (2), AstraZeneca (1) and Jazz Pharmaceuticals (1). Registered phases: Phase 3, Phase 2, Phase 1/2 and Phase 1. Conditions studied include Breast Cancer; Triple Negative Breast Cancer; Breast Neoplasms.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 4 |
| Triple Negative Breast Cancer | 4 |
| Breast Neoplasms | 2 |
| Metastatic Breast Cancer | 2 |
| Soft Tissue Sarcoma (STS) | 2 |
| Metastatic HER2-positive Breast Cancer | 1 |
| Breast Cancer, Metastatic | 1 |
| Locally Advanced Breast Cancer | 1 |
| Metastatic Triple Negative Breast Cancers | 1 |
| HER2-positive Breast Cancer | 1 |
| HER2-positive Gastric Cancer | 1 |
| HER2 Positive Solid Tumors | 1 |
| HER2 Amplification | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Platinum-resistant Ovarian Cancer (PROC) | 1 |
| Endometrial Neoplasms | 1 |
| Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | 1 |
| HER2-negative Breast Cancer | 1 |
| Advanced Breast Cancer | 1 |
| Inoperable Locally Advanced HER2-Negative Breast Cancer | 1 |
| Metastatic HER2-Negative Breast Cancer | 1 |
| Triple Negative Breast Cancer (TNBC) | 1 |
| Breast Cancer Stage IV | 1 |
| Triple -Negative Breast Cancer | 1 |
| Locally Advanced or Metastatic Breast Cancer | 1 |
| HR+HER2- Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| BioNTech SE | 2 |
| AstraZeneca | 1 |
| Jazz Pharmaceuticals | 1 |
| ALX Oncology Inc. | 1 |
| Daiichi Sankyo | 1 |
| Hoffmann-La Roche | 1 |
| Enliven Therapeutics | 1 |
| GI Innovation, Inc. | 1 |
| Advenchen Pharmaceuticals, LLC. | 1 |
| Criterium, Inc. | 1 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 1 |
| Shengjing Hospital | 1 |
| Fudan University | 1 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Sun Yat-sen University | 1 |
| MediLink Therapeutics (Suzhou) Co., Ltd. | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Register | Eribulin trials |
|---|---|
| Clinical trials in China | 13 |
| Clinical trials in USA | 11 |
| Clinical trials in UK | 7 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Eribulin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Eribulin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.